WUXI Biologics (Cayman) Inc. (WUXI BIO) has resolved to deploy its existing repurchase authority to buy back shares on the Hong Kong Stock Exchange for a total consideration of up to US$400 million. The decision was approved on 24 May 2026 and leverages the 10% general repurchase mandate—covering as many as 406.87 million shares—granted by shareholders at the 6 June 2025 annual general meeting.

Management argues that the current market price does not reflect the company’s intrinsic value or business prospects and views the buyback as a signal of confidence in future performance. All repurchases will be executed in compliance with the company’s constitutional documents, Hong Kong Listing Rules, the Codes on Takeovers and Share Buy-backs, the Cayman Islands Companies Act, and other applicable regulations.

Execution parameters, including timing, volume, and price, will be determined at the Board’s discretion and remain subject to prevailing market conditions. The company cautions shareholders and potential investors that there is no assurance on the scale or timing of actual repurchases.